The Obesity Drug That Barely Makes You Nauseous

The key difference patients would notice? The gut doesn't revolt nearly as much.

The Numbers That Matter

The Phase 2 trial, called ZUPREME-1, enrolled about 493 adults with obesity. Five dose arms of petrelintide, one placebo arm, all once-weekly injections for up to 42 weeks. The results, presented by Dr. W. Timothy Garvey in a late-breaking poster (session 3083-LB), told a two-part story.

Part one: it works. Participants on the best-performing dose lost 10.7% of their body weight by week 42, compared to 1.7% on placebo. The trial hit its primary endpoint at week 28, and weight loss kept going.

Part two: it's shockingly easy to tolerate. Only 4.8% of patients on the top dose quit because of side effects, virtually identical to the 4.9% who quit on placebo. Read that again. The drug arm and the sugar-pill arm had the same dropout rate. When you zoom into GI-related dropouts specifically, just 1.5% of petrelintide patients stopped because of stomach issues.

For context, GLP-1 trials typically see GI-related discontinuation rates of 4 to 10%, and some newer incretin combos push north of 20%. Petrelintide's 1.5% is in a different zip code.

Over 75% of GI side effects were mild. Nausea showed up in about 19.6% of patients (compared to 6.2% on placebo), but here's the kicker: vomiting was actually lower on petrelintide (3.0%) than on placebo (6.2%). And once patients hit their maintenance dose, nausea essentially vanished.

The Elephant in the Room: Is 10% Enough?

Let's be honest. A 10.7% weight reduction at 42 weeks is solid, but it's not going to win any arms races. Tirzepatide delivers roughly 20 to 26% weight loss. Novo Nordisk's CagriSema (which, notably, combines a GLP-1 with its own amylin analog, cagrilintide) has shown about 23%. Eli Lilly's amylin candidate eloralintide reportedly hit around 20% in Phase 2.

Wall Street noticed. Zealand's stock dipped after the Phase 2 readout in March, with Jefferies analysts flagging that weight loss came in below expectations.

So why should anyone care about petrelintide?

Because the obesity market isn't just a weight-loss contest. It's a retention game. The best drug in the world doesn't work if patients stop taking it. And right now, patient dropout is the industry's biggest unsolved problem. A drug that keeps 88 to 98% of patients on their target dose through titration (as ZUPREME-1 showed) has real commercial value, even if the scale doesn't move quite as far.

Playing the Long Game

Roche clearly believes in this bet. The company inked a deal worth up to $5.3 billion for petrelintide, including $1.65 billion upfront. Under the partnership, Roche and Zealand split U.S. and European profits 50/50, with Roche taking exclusive rights in the rest of the world. Development milestones tied to Phase 3 initiation could unlock another $1.2 billion.

The strategic play goes beyond monotherapy. Roche has its own incretin candidate, CT-388 (a GLP-1/GIP dual agonist picked up through the Carmot Therapeutics acquisition). The long-term vision? Combine petrelintide with CT-388 in a fixed-dose combo that could deliver GLP-1-level weight loss with amylin-level tolerability. It's a "best of both worlds" thesis that hasn't been tested in humans yet, but the pharmacology makes sense on paper.

A separate poster at ADA 2026 added an interesting mechanistic wrinkle: petrelintide does not appear to delay gastric emptying, which is one of the main drivers of nausea with GLP-1 drugs. If confirmed in larger studies, that finding would explain a lot about the tolerability gap.

What Happens Next

Petrelintide isn't going to dethrone Wegovy or Zepbound anytime soon. Phase 3 trials haven't been publicly detailed yet, and the drug is likely years from market. The amylin obesity space is also getting crowded fast; over $19 billion in deal value has flowed into amylin programs in the past 18 months alone, from Novo, Lilly, Roche, Pfizer, AstraZeneca, and AbbVie.

But tolerability is the kind of advantage that compounds over time. In a world where half of patients quit their obesity drugs within a year, a therapy that feels like placebo to the gut could quietly become the backbone of combination regimens. Not every winning hand has the highest card. Sometimes the winning hand is the one you don't fold.

Lilly's New Weight-Loss Drug Makes Ozempic Look Like a Warm-Up

Eli Lilly's triple-agonist retatrutide just posted 28% average weight loss in a Phase 3 trial, blowing past every GLP-1 drug on the market. The post-Ozempic era officially has a frontrunner.